The agency, in a guidance issued in mid-July, said that Abbott and other makers of unapproved levothyroxine sodium products with New Drug Applications (NDAs) filed but not yet approved must reduce ...
On June 24, The U.S. Food and Drug Administration(FDA) rejected a citizen petition filed in August 2003 regarding bioequivalence of levothyroxine sodium products and approved first-time generic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback